Nat Commun:治疗癌症新思路:移除对肿瘤血管形成关键的蛋白

2015-07-03 佚名 生物谷

近日,来自利兹大学等处的科学家通过研究发现,一种特殊蛋白或可诱发乳腺癌中肿瘤血管的生长,从而促进乳腺癌扩散到大脑中,而乳腺癌向大脑中扩散是其最常见的一种扩散手段,相关研究发表于Nature Communications上。研究者Georgia Mavria表示,通过抑制小鼠模型中DOCK4蛋白,肿瘤血管中的特殊部分就不能够快速形成,从而就会降低肿瘤的生长速度,我们想通过研究阐明肿瘤形成和生长的机制

近日,来自利兹大学等处的科学家通过研究发现,一种特殊蛋白或可诱发乳腺癌中肿瘤血管的生长,从而促进乳腺癌扩散到大脑中,而乳腺癌向大脑中扩散是其最常见的一种扩散手段,相关研究发表于Nature Communications上。

研究者Georgia Mavria表示,通过抑制小鼠模型中DOCK4蛋白,肿瘤血管中的特殊部分就不能够快速形成,从而就会降低肿瘤的生长速度,我们想通过研究阐明肿瘤形成和生长的机制,而本文研究为我们阐明了一种重要的指示器,来帮助阐明该蛋白如何影响大脑中次级乳腺肿瘤的生长,为后期开发新型疗法来抑制乳腺癌向大脑中扩散提供了新的研究思路。

研究者表示,两种蛋白DOCK4和DOCK0的复合体对于血管内腔的形成非常重要,而抑制血管内腔的形成则可有效抑制肿瘤的发展;正常情况下,当乳腺癌扩散到机体其它部位时,其都会驱动新的血管来补给肿瘤,从而导致肿瘤快速发展而难以治疗。而这项研究中研究者揭示了肿瘤血管形成的复杂过程如何被有效控制,如果研究者可以找到一种新型策略来降低向肿瘤的血液供给,那么或可有效抑制癌症的发展和扩散。

每年在英国都有1.2万女性因为乳腺癌而被夺去生命,而在分子水平上来理解乳腺癌的发展对于有效抑制乳腺癌次级肿瘤的形成非常关键;肿瘤需要血管来生长,然而这些血管往往也是癌症的致命弱点,因为其对于许多抗癌药物并不耐受,而靶向作用肿瘤血管的药物可有效抑制肿瘤的血液供给,从而抑制癌症的扩散。

本文研究首次发现名为DOCK4的分子在肿瘤血管的形成过程中扮演着重要角色,通过阻断该分子的功能或可有效抑制肿瘤的生长,但当前研究仅是在小鼠机体中进行的,后期还需要大量研究来检测是否靶向作用DOCK4分子的药物可以有效安全地治疗癌症患者。

原始出处:

Sabu Abraham, Margherita Scarcia, Richard D. Bagshaw,et al.A Rac/Cdc42 exchange factor complex promotes formation of lateral filopodia and blood vessel lumen morphogenesis.Nature Communications.July 1,2015.Article number: 7286 doi:10.1038/ncomms8286

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880716, encodeId=d6231880e166e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 27 05:38:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019290, encodeId=aa1f2019290c9, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Thu Aug 13 07:38:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086803, encodeId=47e12086803f9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 25 07:38:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040912, encodeId=e58620409129c, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Apr 19 02:38:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30478, encodeId=0f28304e8b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30333, encodeId=269f3033350, content=这还是动物研究,到人体上不知道该怎么应用,肿瘤的治疗始终是个难题,我们发现了很多靶点,但是真正能够在临床使用的,却少之又少。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2016-04-27 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880716, encodeId=d6231880e166e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 27 05:38:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019290, encodeId=aa1f2019290c9, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Thu Aug 13 07:38:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086803, encodeId=47e12086803f9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 25 07:38:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040912, encodeId=e58620409129c, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Apr 19 02:38:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30478, encodeId=0f28304e8b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30333, encodeId=269f3033350, content=这还是动物研究,到人体上不知道该怎么应用,肿瘤的治疗始终是个难题,我们发现了很多靶点,但是真正能够在临床使用的,却少之又少。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-08-13 晓辰
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880716, encodeId=d6231880e166e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 27 05:38:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019290, encodeId=aa1f2019290c9, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Thu Aug 13 07:38:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086803, encodeId=47e12086803f9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 25 07:38:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040912, encodeId=e58620409129c, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Apr 19 02:38:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30478, encodeId=0f28304e8b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30333, encodeId=269f3033350, content=这还是动物研究,到人体上不知道该怎么应用,肿瘤的治疗始终是个难题,我们发现了很多靶点,但是真正能够在临床使用的,却少之又少。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2016-03-25 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1880716, encodeId=d6231880e166e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 27 05:38:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019290, encodeId=aa1f2019290c9, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Thu Aug 13 07:38:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086803, encodeId=47e12086803f9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 25 07:38:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040912, encodeId=e58620409129c, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Apr 19 02:38:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30478, encodeId=0f28304e8b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30333, encodeId=269f3033350, content=这还是动物研究,到人体上不知道该怎么应用,肿瘤的治疗始终是个难题,我们发现了很多靶点,但是真正能够在临床使用的,却少之又少。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1880716, encodeId=d6231880e166e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 27 05:38:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019290, encodeId=aa1f2019290c9, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Thu Aug 13 07:38:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086803, encodeId=47e12086803f9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 25 07:38:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040912, encodeId=e58620409129c, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Apr 19 02:38:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30478, encodeId=0f28304e8b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30333, encodeId=269f3033350, content=这还是动物研究,到人体上不知道该怎么应用,肿瘤的治疗始终是个难题,我们发现了很多靶点,但是真正能够在临床使用的,却少之又少。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-07-04 huaxipanxing

    看看

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1880716, encodeId=d6231880e166e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 27 05:38:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019290, encodeId=aa1f2019290c9, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Thu Aug 13 07:38:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086803, encodeId=47e12086803f9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 25 07:38:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040912, encodeId=e58620409129c, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Apr 19 02:38:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30478, encodeId=0f28304e8b5, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 14:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30333, encodeId=269f3033350, content=这还是动物研究,到人体上不知道该怎么应用,肿瘤的治疗始终是个难题,我们发现了很多靶点,但是真正能够在临床使用的,却少之又少。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jul 03 22:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=)]
    2015-07-03 lovetcm

    这还是动物研究,到人体上不知道该怎么应用,肿瘤的治疗始终是个难题,我们发现了很多靶点,但是真正能够在临床使用的,却少之又少。

    0

相关资讯

Cancer Res:鉴别出可促进乳腺癌转移的特殊蛋白

近日,一项发表于国际杂志Cancer Research上的研究论文中,来自隆德大学的研究者通过研究表示,机体肿瘤血管中活化素样受体激酶(ALK1)蛋白处于较高水平的乳腺癌患者或更易发生癌症转移,因此开发抑制ALK1的通路的技术或可作为治疗转移性乳腺癌的新疗法。 研究者Kristian Pietras说道,尽管乳腺癌在早期检测后尽快给予治疗会使得患者的预后良好,但癌症转移是引发90%癌症相关死亡的

Lancet:依西美坦和他莫昔芬治疗女性绝经前早期乳腺癌并接受卵巢抑制的疗效

    背景  TEXT和SOFT试验的疗效相结合分析显示依西美坦加卵巢功能抑制(OFS)与他莫昔芬加上OFS相比有显著无病生存利益。研究人员目前从这些试验的患者报告结果。    方法  在2003年11月7日和2011年4月7日之间,4717例绝经前激素受体阳性的乳腺癌患者被纳入TEXT或SOFT研究接受5年的依西美坦加OFS或他莫昔芬

Br J Cancer:乳腺癌高危女性需戒酒

已有研究发现,饮酒可通过增加乳腺密度的机制来增加患乳腺癌患病风险,但饮酒量与乳腺癌密度之间是如何影响乳腺癌患病风险尚不清楚。 研究人员进行了一项以人群为基础的横断面研究,收纳了来自瑞典年龄在40-74岁的53060名女性。使用问卷调查来评定饮酒量。乳腺密度则用自动测量体积的方法测量。运用Tyrer-Cuzick预测模型来评估未来10年女性患乳腺癌的风险。线性回归模型用来评估饮酒量和乳腺密度和乳腺

PNAS:TLR4——乳腺癌中的“双面人”

近日,来自美国德克萨斯MD安德森癌症中心的研究人员发现抑制免疫受体蛋白TLR4可能并不适用于治疗所有癌,TLR4在乳腺癌中既可促进癌细胞生长也可抑制癌细胞生长,而这种看似矛盾的作用则主要取决于TP53发生的突变类型。这项研究结果最近发表在国际学术期刊PNAS上。   TLR4有许多同家族成员,是参与许多免疫学途径的重要受体分子,之前许多研究证明TLR4是一个癌基因,能够促进肿瘤生长,

Oncotarget:科学家鉴别出可促进乳腺癌发生转移的特殊靶向基因

一种特殊的人类基因突变体或可使乳腺癌细胞变得更加具有攻击性,从而使得乳腺癌细胞不仅对化疗产生耐药,而且使得原发性肿瘤开始扩散;近日来自维也纳医科大学的研究人员通过研究发现,名为AF1q的基因或可使得乳腺癌细胞变得更加具有侵略性,同时该基因或许也可以作为一种新型靶点来帮助开发治疗乳腺癌的靶向性疗法。 人类机体的AF1q基因是在染色体异常时发现的,而且该基因被认为是白血病发生的重要因子,同时研究

Lab Invest:每日服用阿司匹林或可有效抑制乳腺癌的发展

近日,一项刊登在国际杂志Laboratory Investigation上的研究论文中,来自堪萨斯城退伍军人医疗中心的研究人员通过研究发现,每日服用一定的剂量的阿司匹林或可有效阻断乳腺癌的生长,此前研究显示阿司匹林或许对结肠癌、胃肠道癌、前列腺癌等其它癌症均有一定的抑制作用。Banerjee教授说道,在癌症治疗前期阶段一旦尽力去治疗患者,一般肿瘤都会有希望被有效遏制住,但由于癌症干细胞的存在,其往